- Home
- VCRE vs FATE Comparison
VCRE vs FATE Comparison
Compare VCRE & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VCRE | FATE |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.7M | 260.0M |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VCRE | FATE |
|---|---|---|
| Price | $9.44 | $2.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $29.97 | $5.74 |
| AVG Volume (30 Days) | 20.2K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $101.29 | N/A |
| Revenue Next Year | $481.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.88 | $0.95 |
| 52 Week High | $14.01 | $3.23 |
Technical Indicators
Market Signals| Indicator | VCRE | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 43.74 |
| Support Level | $8.70 | $1.78 |
| Resistance Level | $9.64 | $2.15 |
| Average True Range (ATR) | 0.51 | 0.13 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 19.38 | 60.42 |
Price Performance
Historical ComparisonAbout VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.